Use of tianeptine in the production of medicaments to treat neurodegenerative pathologies

• US 6,599,896 B1
• Filed: 08/30/2001
• Issued: 07/29/2003
• Est. Priority Date: 04/07/1999
• Status: Expired due to Fees

• Current Assignee: Les Laboratoires Servier (Servier Sas)
• Original Assignee: Les Laboratoires Servier (Servier Sas)
• Inventors: Deslandes, Antoine, Spedding, Michael
• Primary Examiner(s): HENLEY III, RAYMOND J
• Application Number:
  US09/914,608
• Time in Patent Office: 698 Days
• Field of Search: 514/211.13
• US Class Current: 514/211.13
• CPC Class Codes: A61K 31/554 having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention relates to the use of tianeptine or enantiomers thereof in obtaining medicaments for use in the treatment of neurodegenerative pathologies.

Claims

1. A method for treating a living body afflicted with a neurodegenerative pathology selected from cerebral ischaemia, cerebral traumatism, cerebral aging, Alzheimer'"'"'s disease, multiple sclerosis, amyotrophic lateral sclerosis, demyelating pathologies, encephalopathies, chronic fatigue syndrome, myalgic encephalomyelitis post-viral fatigue syndrome, the state of fatigue following a bacterial or viral infection, and the dementia syndrome of AIDS, consisting of the step of administering, as modulators of these receptors, to the living body an effective amount of a compound selected from tianeptine, its enantiomers, and its addition salts prepared with a pharmaceutically-acceptable acid or base.

2. The method of claim 1 in which the neurodegenerative pathology is amyotrophic lateral sclerosis.

3. The method of claim 1 in which tianeptine is in the form of a sodium salt.